Alexander Gintsburg, head of the Gamaleya Center in Russia, is currently working on a groundbreaking cancer vaccine that utilizes artificial intelligence to treat one of the most well-known diseases of our time. The vaccine will be personalized to each patient’s unique case, with AI programs designed by high-level Russian software experts.
Gintsburg stated that the vaccine will not be administered through an intravenous injection as it would only reach the liver and provide no benefits. Instead, it should be injected directly into the tumor if possible or intramuscularly, as studies have shown this method to be effective in distributing the medication evenly throughout the body. The number of injections needed will depend on the body’s immune response to the vaccine’s components, with one or two injections potentially sufficient for stronger immune responses and up to five injections for weaker responses.
Clinical trials on patients for the vaccine are set to begin by mid-2025. This innovative approach to cancer treatment highlights the potential of combining advanced technology with medical research to develop effective treatments.
